Jhansi

Researchers are evaluating the safety and efficacy of centhaquine citrate LYFAQUIN173, a new drug for treating hypovolemic shock, a serious condition caused by severe blood or fluid loss. This phase IV, prospective, multi-center, open-label study builds on previous findings that centhaquine can improve blood pressure, reduce blood lactate levels, increase cardiac output, and reduce death rates by acting on specific adrenergic receptors to improve blood flow. Participants with hypovolemic shock aged 18 years or older and a systolic blood pressure of 90 mmHg or lower at hospital admission will receive centhaquine in addition to standard shock care. Centhaquine is given intravenously at a dose of 0.01 mgkg body weight over one hour in saline. A second dose may be given if blood pressure remains low, with a maximum of three doses in 24 hours, and treatment can continue for up to two days after enrollment. During hospitalization, participants will be closely monitored and followed until discharge or seven days after enrollment. Researchers will measure safety by tracking adverse events and serious adverse events up to seven days. They will also assess blood pressure, blood lactate, base deficit, time in intensive care, ventilator use, urine output, mortality rates, and organ function scores. Statistical analyses will compare patient outcomes to evaluate centhaquines effects.

Researchers are evaluating the safety and effectiveness of sovateltide also known as PMZ-1620 or IRL-1620 as a potential treatment for acute cerebral ischemic stroke. This phase IV, multicenter, randomized, double-blind study focuses on adults aged 18 to 78 who have experienced an ischemic stroke confirmed by imaging. Sovateltide is being studied because it may activate brain stem cells, promote new neuron and blood vessel growth, prevent cell death, and improve blood flow after stroke, all of which could help brain repair and recovery. The study involves 160 patients split into two groups. One group receives three intravenous doses of sovateltide on days 1, 3, and 6, alongside standard stroke treatment. Each dose is 0.3 micrograms per kilogram of body weight, given over one minute with about three hours between doses, totaling 0.9 micrograms per kilogram daily on those days. The other group receives an equal volume of normal saline on the same schedule plus standard treatment. Patients are monitored closely during the study period for safety and treatment effects. Participants will be followed for three months with three study visits during this time. Researchers will assess stroke severity and recovery using scales like the NIH Stroke Scale, Modified Rankin Scale, and Barthel Index. Safety is tracked by recording adverse events and lab tests, vital signs, and physical exams. The main outcome is the proportion of patients experiencing adverse events within 90 days. The study also evaluates changes in stroke-related scores, quality of life, risk of stroke recurrence, and mortality.